PORTLAND, OREGON, UNITED STATES, July 19, 2024 /EINPresswire.com/ -- European Antibiotics Market Overview

The European Antibiotics Market size was valued at $11,561.2 million in 2019 and is projected to reach $13,529.8 million by 2027, growing at a CAGR of 1.9% from 2020 to 2027. Antibiotics are essential medicines used to combat bacterial infections in humans and animals by either killing bacteria or inhibiting their growth. They are crucial in treating various diseases, including strep throat, urinary tract infections, sinus infections, pneumonia, skin infections, and ear infections.

𝐆𝐞𝐭 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/request-sample/A10311

Market Dynamics

1. Rising Demand:
• The increasing prevalence of infectious diseases is driving the demand for antibiotics.
• Beta lactam and beta lactamase inhibitors are currently in high demand among healthcare providers.
2. COVID-19 Impact:
• The pandemic has led to a significant rise in antibiotic usage, with concerns about increased antimicrobial resistance.
• Studies indicate high antibiotic administration among COVID-19 patients, with common antibiotics including cephalosporins, quinolones, and carbapenems.

3. Challenges:

• The development of antibiotic resistance due to misuse and overuse of antibiotics.
• Lengthy regulatory approval processes hinder market growth.
4. Opportunities:
• Development of novel antibiotics and combination therapies targeting resistant bacterial strains.
• Continuous research and numerous clinical trials are paving the way for new market entrants.

Market Segmentation
1. By Class:
• Beta Lactam & Beta Lactamase Inhibitors: Dominated the market in 2019, expected to maintain its lead due to broad-spectrum activity.
• Quinolones: Projected to witness the fastest growth due to their excellent oral bioavailability and safety profile.
• Macrolides: Another significant class with steady demand.
2. By Drug Origin:
• Semisynthetic: Currently dominates the market, offering improved effectiveness and cost-efficiency.
• Natural: Traditional antibiotics with a narrower scope.
• Synthetic: Emerging with advantages like broad-spectrum activity and low resistance development.
3. By Spectrum of Activity:
• Broad-Spectrum Antibiotics: Effective against a wide range of bacteria.
• Narrow-Spectrum Antibiotics: Target specific bacteria types.
4. By Route of Administration:
• Oral: Preferred for ease of administration.
• Intravenous: Used for severe infections requiring rapid action.
• Others: Includes topical and inhalation routes.

Key Players

The European antibiotics market features several prominent players, including:
• Abbott Laboratories
• Abbvie Inc. (Allergan Plc.)
• Bayer AG
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Merck & Co. Inc.
• Viatris Inc.
• Novartis International AG (Sandoz)
• Pfizer Inc.
• Sanofi

These companies are continuously investing in R&D to introduce new and effective antibiotic treatments to the market.

The European antibiotics market is poised for steady growth, driven by the increasing need for effective treatments against bacterial infections and ongoing innovations in antibiotic therapies. However, challenges like antibiotic resistance and regulatory hurdles must be addressed to sustain this growth. The market's future looks promising with significant opportunities for new and advanced antibiotic developments.

𝐄𝐧𝐪𝐮𝐢𝐫𝐞 𝐁𝐞𝐟𝐨𝐫𝐞 𝐁𝐮𝐲𝐢𝐧𝐠: https://www.alliedmarketresearch.com/purchase-enquiry/A10311

David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
Facebook
X